Matrix metalloproteinases play a key role in diabetic vascular complications, and their modulation by current therapies or specific inhibitors represents a potential therapeutic target.
Cardiovascular complications are the leading cause of increasing and premature mortality in diabetic patients. Matrix metalloproteinases (MMPs) play an important role in the development and progression of vascular lesions. Matrix metalloproteinases are members of endopeptidases and are capable of degrading many extracellular matrix components. Results of recent studies indicated that non-pharmacological and pharmacological treatment of diabetes influenced disturbed system of metalloproteinases and their inhibitors. Clinical trials are being performed in hope that the selective MMP inhibitors reduce the progression of pathological vascular remodeling in diabetes. Further basic and clinical research is required to confirm hypothesis.
No takes yet. Share an insight, caveat, or question.
Rogowicz et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: